

You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Antibody Characterization Report for Ubiquilin-2
Antibody Characterization Report for Ubiquilin-2
Head-to-head comparison of available commercial antibodies against Ubiquilin-2 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. The workflow and data collected in this study was used to create an article published on F1000, DOI: 10.12688/f1000research.131851.1. The following study was funded in part by Genome Québec's Genomics Integration Program, awarded to the research laboratory of Peter S. McPherson. This work was supported by the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities: the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
Protein linking IAP with cytoskeleton 2, amyotrophic lateral sclerosis, antibody characterization, Q9UHD9, Ubiquilin-2, Chap1, antibody validation, ALS-RAP, UBQLN2, DSK2 homolog
Protein linking IAP with cytoskeleton 2, amyotrophic lateral sclerosis, antibody characterization, Q9UHD9, Ubiquilin-2, Chap1, antibody validation, ALS-RAP, UBQLN2, DSK2 homolog
17 Research products, page 1 of 2
- 2022IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2023IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average visibility views 67 download downloads 77 citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average Powered byBIP!
- 67views77downloads



Head-to-head comparison of available commercial antibodies against Ubiquilin-2 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. The workflow and data collected in this study was used to create an article published on F1000, DOI: 10.12688/f1000research.131851.1. The following study was funded in part by Genome Québec's Genomics Integration Program, awarded to the research laboratory of Peter S. McPherson. This work was supported by the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities: the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.